Plus: Unravel Health raises €2.96M for at-home hormone testing, Organon's MIUDELLA IUD sNDA reaches FDA review, and Lilly advances its ovarian cancer ADC
Allara raised $30 million to bring its total funding to $75 million, deploying capital into AI tools and clinical research that challenge traditional outpatient gynecology workflows. Decentralized endocrine management is converging around patient-led monitoring, where Unravel Health's €2.96 million seed round for saliva hormone testing pairs with virtual clinic scale to bypass legacy lab delays. At the regulatory level, Organon advanced long-acting contraception into FDA review, with an extended-duration sNDA decision for the MIUDELLA IUD slated for Q2 2027. Five takes inside, plus a quick-hits roundup.
VIA EU-Startups
Unravel Health raised €2.96 million (£2.5 million) in funding co-led by Conduit EIS Impact Fund and Wrightwood to develop its at-home saliva hormone testing device, the Micro Lab. Based on technology developed over ten years at the University of Glasgow and protected by three granted patents, the device measures oestradiol alongside three other hormones simultaneously. The company will use the capital to fund external equivalency studies, develop additional markers, and initiate regulatory approval ahead of an early-access rollout in 2027 through pharmacy, digital health, and clinical research partners.
Read the full story →
— The Luteal Editorial Team
VIA FemTech World
Allara raised US$30 million from investors including GV, Index Ventures, and Camino Partners, bringing the virtual healthcare company's total funding to US$75 million. The platform has treated more than 120,000 women for hormonal, metabolic, and reproductive conditions, and expanded its services to include GLP-1 medications, hormone replacement therapy, and virtual urgent care. Allara will use the capital to develop AI tools and fund clinical research on conditions including PCOS and endometriosis, serving a patient population where 80 percent of surveyed women who consulted prior providers reported their symptoms were dismissed or minimized.
Read the full story →
— The Luteal Editorial Team
VIA PR Newswire – Health
Lilly will present first Phase 1 data for sofetabart mipitecan, an investigational FRα-targeting ADC, in platinum-sensitive ovarian cancer in a rapid oral presentation. The company will also present updated first-line data for olomorasib, an investigational therapy targeting KRAS G12C-mutant NSCLC.
Read the full story →
— The Luteal Editorial Team
VIA Contemporary OB/GYN
The FDA accepted an extended duration supplemental New Drug Application (sNDA) for Organon's MIUDELLA IUD in September. The agency anticipates issuing a regulatory decision in Q2 2027.
Read the full story →
— The Luteal Editorial Team
VIA Nature Medicine
A Phase 1 clinical trial demonstrated that treating high-grade serous ovarian cancer patients with personalized neoantigen vaccines combined with PD-1 blockade is feasible and generates tumor-specific immune responses. Additionally, cell-free DNA analysis identified putative resistance mechanisms related to antigen presentation.
Read the full story →
— The Luteal Editorial Team